---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-164835"
form_type: "8-K"
ticker: "KURA"
cik: "0001422143"
company_name: "Kura Oncology, Inc."
filed_at: "2023-06-12T23:59:59+00:00"
generated_at: "2026-06-14T02:51:32.021898+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Kura Oncology reports 35% CR rate with ziftomenib in NPM1-mutant AML at EHA 2023

## Summary
- 7 of 20 NPM1-mutant AML patients at 600 mg RP2D achieved complete remission (CR) with full count recovery.
- Median duration of response 8.2 months; median follow-up 8.8 months; 2 patients underwent SCT and remain in remission.
- MEN1-M3271 resistance mutation detected in only 1 of 29 patients post-ziftomenib; ziftomenib active against MEN1-T349M.
- Phase 2 registration-directed study (85 patients, 62 sites) enrollment outperforming projections; combination studies initiating.
- Differentiation syndrome manageable: 15% Grade 1/2, 5% Grade 3; safety profile consistent with underlying disease.

## SEC filing metadata
- accession: 0001193125-23-164835
- form_type: 8-K
- ticker: KURA
- cik: 0001422143
- company_name: Kura Oncology, Inc.
- filed_at: 2023-06-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1422143/000119312523164835/0001193125-23-164835-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1422143/000119312523164835/d450277d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-164835
- JSON: https://secwatch.observer/filing/0001193125-23-164835.json
- Plain text: https://secwatch.observer/filing/0001193125-23-164835.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.